Invited speakers and session chairs
Professor John Fisher CBE FREng FMedSci FIMechE FIPEM CEng, is Director of the Institute of Medical and Biological Engineering (iMBE) and Deputy Vice Chancellor at the University of Leeds. He is Director of the following EPSRC research centres: IKC Innovation and Knowledge Centre in Medical Technologies, Centre for Innovative Manufacturing in Medical Devices, Centre for Doctoral Training in Tissue Engineering & Regenerative Medicine and is Executive Director of Regener8. John’s research interests include pre-clinical simulation and testing in joint replacements and regenerative devices and he holds a grant portfolio of £50m. He has started four spin- out companies, collaborates and consults with companies across the globe, has published over four hundred journal papers and supervised over 100 PhD students.
Professor Eileen Ingham holds a chair in Medical Immunology at the University of Leeds with an international reputation in the fields of biocompatibility of medical implants. She is inventor on 8 patent families, has published 280 peer reviewed papers and has supervised around 70 PhD/MD research students. She is co-founder and Deputy Director of the Institute of Medical & Biological Engineering (iMBE) at Leeds and has a long-standing collaboration with the NHS National Blood & Tissue Services to whom she has licensed platform technologies for the decellurisation of allografts. She is an academic founder of spin-out company Tissue Regenix Group PLC, which is commercialising acellular biological scaffold technology.
Professor Jennifer Southgate began her career at the Imperial Cancer Research Fund (ICRF) in London. From 1992 she led the Biology of Normal and Malignant Epithelial
Cells research group at St James’s University Hospital. In 1999, she was appointed Chair of Molecular Carcinogenesis as Director of the Jack Birch Unit, a research unit sponsored by York Against Cancer. Her research focuses on cellular regulation of tissue homeostasis in health and disease and developing cell and tissue culture systems for normal human urothelium.
Mr Ramnath Subramaniam is a Consultant Paediatric Urologist at Leeds Teaching Hospitals NHS Trust and Honorary Clinical Associate Professor at University of Leeds. His main clinical areas of specialisation are minimally invasive surgery and reconstructive paediatric urology. He is currently Chairman for Education and Training in Europe under the umbrella of European Society of Paediatric Urology. His research interests include bladder tissue engineering in collaboration with the Universities of York and Leeds, and biomaterials in reconstructive lower urinary tract surgery.
Dr Paul Rooney is Research and Development Manager at the National Blood Service. He is a registered Clinical Scientist and runs the Tissue Development Laboratory which performs validations on existing tissue grafts and processes and is involved in new tissue graft development. After his PhD he spent 20 years in academic research into connective tissues, particularly bone and cartilage. Paul holds an Honorary Lectureship from Manchester University, and is Honorary Associate Professor at the University of Leeds. He has published more than 60 scientific articles on connective tissue research and is associated with some £7 million in research grants.
Professor Mike Raxworthy is Operations Director of Regener8. A biomedical scientist with PhD from the University of Leeds, he has nearly 30 years’ experience leading R&D in the medical device and pharmaceutical industries, and became involved in tissue engineering in 1996. He has an MBA from Warwick Business School and is founder and CEO of Neotherix Ltd, spun-out from Smith & Nephew in 2007, which produces bioresorbable regenerative scaffolds for tissue repair. He was awarded an RAEng Visiting Professorship in Medical Technology Innovation and Translation at the University of Leeds in 2015.
John Wilkinson joined the MHRA from Eucomed, the European medical technology industry association, where he was Chief Executive. His earlier experience includes Director General of the Association of British Healthcare Industries and a number of roles in the medical devices industry, both in the UK and the USA, with Becton Dickinson and the BOC Group.
Dr Steve Bloor has over 20 years’ experience in the medical device and regenerative medicine industry having worked within both start up and multinational medical companies. Dr Bloor has a proven track record of innovation leadership and senior management including Vice President R&D at Covidien and Chief Scientific Officer for TSL (AIM listed SME) with direct responsibility for R&D, Regulatory, Clinical and Compliance functions. Dr Bloor founded Videregen Ltd in 2011 to develop and commercialise advanced organ replacement technologies.
Dr Itoro Udofia is the Head of Medical Device Operations and Training at BSI. He has over fifteen years’ experience working with orthopaedics devices, as a Technical Specialist working in medical devices and as Head of the Orthopaedics and Dental devices team. Itoro’s academic research includes biomedical engineering, biotribology and computational modelling of orthopaedic devices. He worked as a research consultant with leading orthopaedic manufacturers in product development and testing, publishing numerous scientific papers and has delivered presentations and workshops at international conferences on European medical device regulations.
Dr Simon Chandler is Director, New Business & Partnership at IP Group. He works closely
with IP Group’s university partners to identify, validate and accelerate the commercial exploitation of new healthcare technologies through the formation of spin-out technology companies. Before joining IP Group he held commercial positions within the biotechnology and pharmaceutical industries. He has worked to develop entirely new market sectors for cutting-edge genomics technologies at both Bio-Rad laboratories and Applied Biosystems, and to develop the early-stage advanced therapeutics/biotechnology business in Europe for Covance Laboratories.
Phil Brown is Director, Technical and Regulatory at the Association of British Healthcare Industries (ABHI). He has worked in the fields of Regulatory Affairs, Quality Assurance and Compliance for global medical device companies for over 25 years, including roles at Smith & Nephew, Genzyme Biosurgery, D-Target, Quintiles and Wright Medical, where he was responsible for Regulatory Affairs, Quality Assurance, Reimbursement and Compliance across the EMEA region.
Dr Stephen Simpson is Director of Research, Arthritis Research UK (ARUK). He is responsible for leading the development and effective implementation of research at the charity, including new areas of research translation and partnership funding. Stephen was formerly Director of Life Sciences at Science Foundation Ireland (SFI), where he led the core objectives of the Foundation in delivering research excellence in the life sciences, and sustaining economic relevance and growth of Irish research. He was also editor of the international journal Science for eight years.
Dr Frances Henson is Senior Lecturer in the Department of Veterinary Medicine, University of Cambridge and a Research Fellow in the Division of Trauma and Orthopaedic Surgery, Department of Surgery, University of Cambridge. Her research interest is in the healing of joint surface defects in both man and animals, both from the molecular control of bone and cartilage healing to in vivo experiments assessing efficacy of novel treatments.
Dr Chaozong Liu is a non-clinical senior lecturer at UCL Division of Surgery & Interventional Science, the Royal National Orthopaedic Hospital. His research is directed toward biomedical devices development
for enhancing treatment of musculoskeletal disorders. Core activities include: (1) scaffold innovation for musculoskeletal tissue regeneration; (2) Customized medical devices for intervention of orthopaedic disorders. (3) Biomedical device surface processing for enhancing in vivo service functions.
Paul F. McMillan is Ramsay Professor of Chemistry at University College London. He graduated with Chemistry BSc from Edinburgh University (1977) and his PhD degree (geochemistry) at Arizona State University (1981). There he studied the structure of aluminosilicate glasses using Raman spectroscopy. In 2000 he moved to London to a UCL Chair in Solid State Chemistry, held jointly with the Royal Institution. He also began to expand his research interests into biophysics and biology, including Raman spectroscopy for biomedical applications.
Dr Abi Spear is a Principal Scientist in the Medical Sciences programme at the Defence, Science and Technology Laboratory (Dstl), an agency of the Ministry of Defence. Abi studied Biochemistry at the University of Oxford and has a PhD from the London School of Hygiene and Tropical Medicine. Her research focuses on the molecular and cellular biology of trauma. She recently received a Frontiers Innovator award from the Wellcome Trust.
Dr Alex Knight completed a PhD in Molecular Biology at the MRC-LMB in 1994, followed by post-docs at the Whitehead Institute and the University of York. He is currently a Principal Research Scientist at the National Physical Laboratory and is Chief Investigator and Project Manager for the NIHR i4i RegeniTherix project. His research at NPL includes point-of-care diagnostics, super-resolution microscopy, and the application of metrology to the life sciences.
Dr Thomas Baboolal’s research is focused on the role of mesenchymal stem cells (MSCs) in cartilage, bone and soft tissue repair. In particular, he focuses on how by understanding MSC biology, repair of these tissue can be better augmented using devices or biological therapeutics. Thomas is involved in all facets of research from basic science to clinical translation including medical device trials.
8 – 9
regen. Issue 7
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17